DD

Business profile & competitive position

DuPont de Nemours, Inc. (DD) is classified in the Basic Materials sector, Chemicals industry. The company supplies advanced solutions for healthcare, water, construction and industrial end markets and now operates through two reportable segments: Healthcare & Water Technologies and Diversified Industrials. Its Electronics business, Aramids business and historical M&M businesses have been treated as discontinued operations, so the continuing portfolio centers on medical packaging and devices, water filtration and purification products, building-envelope and interior solutions, and industrial adhesives, lubricants, engineered shapes and printing plates.

The current numbers paint a company in transition rather than one firing on all cylinders. Net margin is just 0.7% and ROE is only 0.3%, both extremely low for an advanced-materials enterprise. Those figures suggest that, despite its brand and technology base, DuPont is not currently converting revenue into strong returns for shareholders. One durable asset is intellectual property: the company owns roughly 6,100 patents and patent applications globally, of which about 4,700 relate to continuing operations, and more than 70% of the continuing-operations patent estate has a remaining term of more than five years. That patent base is a real differentiator, but the thin margins and low ROE show that differentiation has not yet translated into robust profitability.

Financial posture

DuPont currently carries a market capitalization of $19.3 billion, with the stock recently trading at $143.09. The price-to-earnings ratio of 311.1 is exceptionally high and is consistent with the company’s near-zero net margin and near-zero ROE. At that multiple, the market appears to be pricing in significant margin recovery and value creation from the post-separation portfolio rather than simplyrewarding current earnings. The stock’s beta is 1.09, implying modestly higher sensitivity to broad market moves. In the current technical snapshot, the 50-day exponential moving average is $140.91 and the RSI is 54.0, a neutral reading.

Strategic priorities & outlook

DuPont’s most recent 10-K filing lays out four near-term priorities. First, it aims to complete the sale of its Aramids business to Arclin, which was expected around the end of the first quarter of 2026, subject to regulatory approvals and customary closing conditions. Second, it is working to realize the intended benefits of the Electronics separation, including the desired tax treatment and the contractual allocation of certain liabilities to Qnity. Third, management intends to execute the $2 billion share-buyback authorization announced on November 6, 2025. Fourth, the company must manage a cost-sharing arrangement for future eligible PFAS liabilities among DuPont, Corteva and Chemours, which includes litigation and remediation exposures.

Operationally, DuPont realigned into two reportable segments effective in the fourth quarter of 2025 and recast historical financial statements as if the M&M, Aramids and Electronics separations had occurred on January 1, 2023. As of December 31, 2025, it had subsidiaries in about 50 countries, manufacturing operations in about 20 countries and approximately 15,000 employees worldwide, including about 1,700 dedicated to the Aramids business. The restructuring therefore has a real footprint and is not simply a paper reorganization.

Macro & geopolitical exposure

As a diversified global chemicals company, DuPont is exposed to several macro and geopolitical forces. Its footprint in about 50 countries means that currency translation, cross-border trade policy and tariffs can affect both revenue and input costs. The Chemicals industry is also heavily exposed to environmental and product-safety regulation; the PFAS-related litigation and remediation arrangements discussed in the 10-K are a direct example of how chemical producers can face large, multi-year liability risks. In addition, the sector is sensitive to specialty feedstock prices, energy costs and logistics. Finally, demand from downstream markets—healthcare, water infrastructure, construction and industrial manufacturing—will move with capital spending cycles, infrastructure budgets and healthcare policy.

Recent developments

Recent headlines have underscored two themes: commercial momentum in water treatment and ongoing PFAS legal exposure. On August 7, 2026, Reuters reported that New Jersey’s $2.5 billion “forever chemicals” settlements with DuPont, 3M and others won court approval, a notable milestone in the company’s PFAS liability management. On August 11, 2026, PRNewswire announced that Australia’s largest inland wastewater treatment facility selected DuPont’s MemCor™ MBR system for expansion. On August 13, 2026, DuPont’s Direct Lithium Extraction team was named a 2026 Sustainability Squad by the Business Intelligence Group. And on August 17, 2026, Zacks reported that DD’s MemCor MBR System was chosen for a major plant upgrade in Australia. Together, these items show active order flow in water filtration alongside continued legal settlement activity on PFAS.

Earnings behavior & post-earnings drift

DuPont has an unusual earnings track record over the last eight reported quarters: it beat consensus in all eight quarters, for a beat rate of 100%, and the average earnings surprise was 171.1%. The average five-day price move after those reports was 2.83%, classified as an upward post-earnings drift. That pattern reflects a recurring gap between conservative estimates and stronger-than-expected actual results, though it does not necessarily predict future performance.

The most recent four quarters illustrate the dynamic. On November 6, 2025, the company reported EPS of $3.27 versus a consensus estimate of $0.4656, a 602.3% surprise; the stock rose 1.66% the next session and 3.70% over the following five days. On February 10, 2026, EPS came in at $1.38 versus $1.29 estimated, a 7.0% surprise, and the stock gained 4.25% the next day and 3.88% over five days. On May 5, 2026, DuPont earned $1.65 per share versus an estimate of $0.4881, a 238% surprise, with the stock up 1.69% the next day and 2.64% over five days. The most recent report, on August 4, 2026, delivered $1.88 against $1.76 estimated, a 6.8% surprise, and the stock moved 3.11% the next day but only 1.09% over the subsequent five sessions. The next scheduled release is November 5, 2026, before the market open, with a consensus EPS estimate of $1.87.

For a deeper dive into how institutional analysts are interpreting DuPont’s portfolio separation, valuation and litigation exposure, review the full institutional verdict on the ticker page.